| Title |
Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults
|
|---|---|
| Published in |
Journal of General Internal Medicine, April 2015
|
| DOI | 10.1007/s11606-015-3335-1 |
| Pubmed ID | |
| Authors |
Ishak Mansi, Christopher R. Frei, Chen-Pin Wang, Eric M. Mortensen |
| Abstract |
Statin use is associated with increased incidence of diabetes and possibly with increased body weight and reduced exercise capacity. Data on the long-term effects of these associations in healthy adults, however, are very limited. In addition, the relationship between these effects and diabetic complications has not been adequately studied. To examine the association between statin use and new-onset diabetes, diabetic complications, and overweight/obesity in a cohort of healthy adults. This was a retrospective cohort study. Subjects were Tricare beneficiaries who were evaluated between October 1, 2003 and March 1, 2012. Patients were divided into statin users and nonusers. We excluded patients who, at baseline, had a preexisting disease indicative of cardiovascular diseases, any positive element of the Charlson comorbidity index (including diabetes mellitus), or life-limiting chronic diseases. Using 42 baseline characteristics, we generated a propensity score to match statin users and nonusers. Outcomes assessed included new-onset diabetes, diabetic complications, and overweight/obesity. A total of 25,970 patients (3982 statin users and 21,988 nonusers) were identified as healthy adults at baseline. Of these, 3351 statins users and 3351 nonusers were propensity score-matched. Statin users had higher odds of new-onset diabetes (odds ratio [OR] 1.87; 95 % confidence interval [95 % CI] 1.67-2.01), diabetes with complications (OR 2.50; 95 % CI 1.88-3.32), and overweight/obesity (OR 1.14; 95 % CI 1.04-1.25). Secondary and sensitivity analyses demonstrated similar findings. Diabetes, diabetic complications, and overweight/obesity were more commonly diagnosed among statin-users than similar nonusers in a healthy cohort of adults. This study demonstrates that short-term clinical trials might not fully describe the risk/benefit of long-term statin use for primary prevention. |
X Demographics
The data shown below were collected from the profiles of 71 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 13% |
| United Kingdom | 9 | 13% |
| Australia | 5 | 7% |
| South Africa | 4 | 6% |
| Netherlands | 4 | 6% |
| Canada | 3 | 4% |
| France | 2 | 3% |
| Bosnia and Herzegovina | 1 | 1% |
| Thailand | 1 | 1% |
| Other | 7 | 10% |
| Unknown | 26 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 54 | 76% |
| Practitioners (doctors, other healthcare professionals) | 10 | 14% |
| Scientists | 7 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Germany | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 151 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 14% |
| Student > Bachelor | 20 | 13% |
| Student > Ph. D. Student | 18 | 12% |
| Other | 16 | 10% |
| Researcher | 16 | 10% |
| Other | 33 | 21% |
| Unknown | 30 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 37% |
| Nursing and Health Professions | 21 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 6% |
| Psychology | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 6 | 4% |
| Other | 17 | 11% |
| Unknown | 37 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 101. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2024.
All research outputs
#425,382
of 25,744,802 outputs
Outputs from Journal of General Internal Medicine
#338
of 8,247 outputs
Outputs of similar age
#4,601
of 280,077 outputs
Outputs of similar age from Journal of General Internal Medicine
#6
of 119 outputs
Altmetric has tracked 25,744,802 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,247 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,077 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 119 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.